{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:13:14Z","timestamp":1774447994600,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H01551"],"award-info":[{"award-number":["18H01551"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This paper studies the social acceptability and feasibility of a focused protection strategy against coronavirus disease 2019 (COVID-19). We propose a control scheme to develop herd immunity while satisfying the following two basic requirements for a viable policy option. The first requirement is social acceptability: the overall deaths should be minimized for social acceptance. The second is feasibility: the healthcare system should not be overwhelmed to avoid various adverse effects. To exploit the fact that the disease severity increases considerably with age and comorbidities, we assume that some focused protection measures for those high-risk individuals are implemented and the disease does not spread within the high-risk population. Because the protected population has higher severity ratios than the unprotected population by definition, the protective measure can substantially reduce mortality in the whole population and also avoid the collapse of the healthcare system. Based on a simple susceptible-infected-recovered model, social acceptability and feasibility of the proposed strategy are summarized into two easily computable conditions. The proposed framework can be applied to various populations for studying the viability of herd immunity strategies against COVID-19. For Japan, herd immunity may be developed by the proposed scheme if\n                    <jats:inline-formula>\n                      <jats:alternatives>\n                        <jats:tex-math>$${\\mathcal {R}}_0 \\le 2.0$$<\/jats:tex-math>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                          <mml:mrow>\n                            <mml:msub>\n                              <mml:mi>R<\/mml:mi>\n                              <mml:mn>0<\/mml:mn>\n                            <\/mml:msub>\n                            <mml:mo>\u2264<\/mml:mo>\n                            <mml:mn>2.0<\/mml:mn>\n                          <\/mml:mrow>\n                        <\/mml:math>\n                      <\/jats:alternatives>\n                    <\/jats:inline-formula>\n                    and the severity rates of the disease are 1\/10 times smaller than the previously reported value, although as high mortality as seasonal influenza is expected.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-81630-9","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T06:03:39Z","timestamp":1611209019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Model-based analysis on social acceptability and feasibility of a focused protection strategy against the COVID-19 pandemic"],"prefix":"10.1038","volume":"11","author":[{"given":"Takashi","family":"Akamatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nagae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Satsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takara","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daijiro","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"81630_CR1","unstructured":"World Health Organization. Coronavirus disease (COVID-2019) situation report 162 (10:00 CEST, June 30, 2020). https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports\/."},{"key":"81630_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1098\/rspb.2006.0015","volume":"274","author":"A Handel","year":"2007","unstructured":"Handel, A., Longini Jr., I. M. & Antia, R. What is the best control strategy for multiple infectious disease outbreaks? Proc. R. Soc. B Biol. Sci. 274, 833\u2013837 (2007).","journal-title":"Proc. R. Soc. B Biol. Sci."},{"key":"81630_CR3","unstructured":"Ferguson, N., Laydon, D., Nedjati Gilani, G. et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. Tech. Rep., Imperial College London (March 16, 2020)."},{"key":"81630_CR4","unstructured":"Walker, P. G., Whittaker, C., & Watson, O. et al. Report 12: The global impact of COVID-19 and strategies for mitigation and suppression. Tech. Rep., Imperial College London (March 26, 2020)."},{"key":"81630_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41591-020-0871-y","volume":"26","author":"M Gilbert","year":"2020","unstructured":"Gilbert, M., Dewatripont, M., Muraille, E., Platteau, J.-P. & Goldman, M. Preparing for a responsible lockdown exit strategy. Nat. Med. 26, 643\u2013644 (2020).","journal-title":"Nat. Med."},{"key":"81630_CR6","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","volume":"395","author":"A Remuzzi","year":"2020","unstructured":"Remuzzi, A. & Remuzzi, G. COVID-19 and Italy: What next? Lancet 395, 1225\u20131228 (2020).","journal-title":"The Lancet"},{"key":"81630_CR7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199\u20131207 (2020).","journal-title":"N. Engl. J. Med."},{"key":"81630_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(20)30260-9","volume":"395","author":"JT Wu","year":"2020","unstructured":"Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 395, 689\u2013697 (2020).","journal-title":"Lancet"},{"key":"81630_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","volume":"20","author":"R Verity","year":"2020","unstructured":"Verity, R. et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect. Dis. 20, 669\u2013677 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"81630_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2807\/1560-7917.ES.2020.25.12.2000256","volume":"25","author":"TW Russell","year":"2020","unstructured":"Russell, T. W. et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance 25, 6\u201310 (2020).","journal-title":"Eurosurveillance"},{"key":"81630_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1126\/science.abc3517","volume":"369","author":"H Salje","year":"2020","unstructured":"Salje, H. et al. Estimating the burden of SARS-CoV-2 in France. Science 369, 208\u2013211 (2020).","journal-title":"Science"},{"key":"81630_CR12","unstructured":"Centers for Disease Control and Prevention. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) United States, february 12-march 16, 2020 (2020). https:\/\/www.cdc.gov\/flu\/about\/burden\/past-seasons.html (accessed November 19, 2020)."},{"key":"81630_CR13","first-page":"700","volume":"115","author":"WO Kermack","year":"1927","unstructured":"Kermack, W. O. & McKendrick, A. G. A contribution to the mathematical theory of epidemics. Proc. R. Soc. Ser. A 115, 700\u2013721 (1927).","journal-title":"Proc. R. Soc. Ser. A"},{"key":"81630_CR14","doi-asserted-by":"crossref","unstructured":"Handel, A., Miller, J., Ge, Y. & Fung, I. C.-H. If long-term suppression is not possible, how do we minimize mortality for COVID-19 and other emerging infectious disease outbreaks? medRxiv (2020).","DOI":"10.1101\/2020.03.13.20034892"},{"key":"81630_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2020.04.012","volume":"52","author":"HE Randolph","year":"2020","unstructured":"Randolph, H. E. & Barreiro, L. B. Herd immunity: understanding COVID-19. Immunity 52, 737\u2013741 (2020).","journal-title":"Immunity"},{"key":"81630_CR16","unstructured":"Ministry of Internal Affairs and Communications. Annual report: Population estimates (2019). https:\/\/www.e-stat.go.jp\/."},{"key":"81630_CR17","doi-asserted-by":"crossref","unstructured":"Streeck, H. et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. medRxiv (2020).","DOI":"10.1101\/2020.05.04.20090076"},{"key":"81630_CR18","doi-asserted-by":"publisher","first-page":"2000180","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000180","volume":"25","author":"K Mizumoto","year":"2020","unstructured":"Mizumoto, K., Kagaya, K., Zarebski, A. & Chowell, G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance 25, 2000180 (2020).","journal-title":"Eurosurveillance"},{"key":"81630_CR19","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1056\/NEJMc2009316","volume":"382","author":"D Sutton","year":"2020","unstructured":"Sutton, D., Fuchs, K., D\u2019Alton, M. & Goffman, D. Universal screening for SARS-CoV-2 in women admitted for delivery. N. Engl. J. Med. 382, 2163\u20132164 (2020).","journal-title":"N. Engl. J. Med."},{"key":"81630_CR20","doi-asserted-by":"crossref","unstructured":"Doi, A. et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study. medRxiv (2020).","DOI":"10.1016\/j.cegh.2021.100747"},{"key":"81630_CR21","unstructured":"Ministry of Health, Labour and Welfare. Number of beds for novel coronavirus infections (2020). https:\/\/www.mhlw.go.jp\/content\/10900000\/000628694.pdf (accessed May 14, 2020)."},{"key":"81630_CR22","unstructured":"Altstedter, A. Infect everyone: How herd immunity could work for poor countries. Bloomberg (21 April 2020). https:\/\/www.bloomberg.com\/news\/articles\/2020-04-21\/a-herd-immunity-strategy-could-actually-work-in-youthful-india (accessed April 23, 2020)."},{"key":"81630_CR23","doi-asserted-by":"publisher","first-page":"e1003","DOI":"10.1016\/S2214-109X(20)30264-3","volume":"8","author":"A Clark","year":"2020","unstructured":"Clark, A. et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Global Health 8, e1003\u2013e1017 (2020).","journal-title":"Lancet Global Health"},{"key":"81630_CR24","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.abb5793","volume":"368","author":"SM Kissler","year":"2020","unstructured":"Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of sars-cov-2 through the postpandemic period. Science 368, 860\u2013868 (2020).","journal-title":"Science"},{"key":"81630_CR25","unstructured":"Acemoglu, D., Chernozhukov, V., Werning, I. & Whinston, M. D. A multi-risk SIR model with optimally targeted lockdown. Tech. Rep., National Bureau of Economic Research (2020)."},{"key":"81630_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0236237","volume":"15","author":"M Chikina","year":"2020","unstructured":"Chikina, M. & Pegden, W. Modeling strict age-targeted mitigation strategies for COVID-19. PLOS ONE 15, 1\u201317 (2020).","journal-title":"PLoS ONE"},{"key":"81630_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1473-3099(20)30322-4","volume":"20","author":"AK Winter","year":"2020","unstructured":"Winter, A. K. & Hegde, S. T. The important role of serology for COVID-19 control. Lancet Infect. Dis. 20, 758\u2013759 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"81630_CR28","unstructured":"Grassly, N. C., Pons-salort, M., Parker, E. P. K., White, P. J. et al. Report 16: Role of testing in COVID-19 control. Tech. Rep., Imperial College London (23 April 2020)."},{"key":"81630_CR29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1126\/science.abc6810","volume":"369","author":"T Britton","year":"2020","unstructured":"Britton, T., Ball, F. & Trapman, P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science 369, 846\u2013849 (2020).","journal-title":"Science"},{"key":"81630_CR30","doi-asserted-by":"crossref","unstructured":"Gomes, M. G. M. et al. Individual variation in susceptibility or exposure to sars-cov-2 lowers the herd immunity threshold. medRxiv (2020).","DOI":"10.1101\/2020.04.27.20081893"},{"key":"81630_CR31","doi-asserted-by":"crossref","unstructured":"Brennan, P. V. & Brennan, L. P. Susceptibility-adjusted herd immunity threshold model and potential R0 distribution fitting the observed Covid-19 data in Stockholm. medRxiv (2020).","DOI":"10.1101\/2020.05.19.20104596"},{"key":"81630_CR32","unstructured":"Kulldorff, M., Gupta, S. & Bhattachary, J. Great Barrington Declaration (10:00 CEST, October 4, 2020). https:\/\/gbdeclaration.org\/ (accessed October 16, 2020)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81630-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81630-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81630-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T21:18:44Z","timestamp":1670015924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81630-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81630"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81630-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.19.20107524","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2003"}}